StockNews.com Initiates Coverage on VBI Vaccines (NASDAQ:VBIV)

Stock analysts at StockNews.com began coverage on shares of VBI Vaccines (NASDAQ:VBIV) in a research report issued on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

VBI Vaccines Trading Up 2.6 %

NASDAQ:VBIV opened at $0.75 on Friday. The business’s fifty day moving average is $0.63 and its 200 day moving average is $0.62. VBI Vaccines has a 52-week low of $0.45 and a 52-week high of $1.54.

VBI Vaccines (NASDAQ:VBIV) last announced its quarterly earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.02). VBI Vaccines had a negative net margin of 881.79% and a negative return on equity of 525.42%. The company had revenue of $1.21 million for the quarter, compared to the consensus estimate of $2.85 million. Research analysts forecast that VBI Vaccines will post -1.23 earnings per share for the current year.

VBI Vaccines Company Profile

VBI Vaccines Inc, a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.